S&P Futures
4,060.75 -14.75 (-0.36%) Dow Futures
33,970.00 -53.00 (-0.16%) Nasdaq Futures
12,031.75 -75.00 (-0.62%) Russell 2000 Futures
1,904.60 -5.90 (-0.31%) Crude Oil
81.97 +0.96 (+1.19%) Gold
1,926.40 -3.60 (-0.19%)
Jaguar Health, Inc. (JAGX)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 4.9600 |
| Open | 5.0300 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 1200 |
| Day's Range | 4.4500 - 5.0710 |
| 52 Week Range | 4.4500 - 66.7500 |
| Volume | |
| Avg. Volume | 152,720 |
| Market Cap | 207.879M |
| Beta (5Y Monthly) | 1.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0000 |
| Earnings Date | Mar 09, 2023 - Mar 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- ACCESSWIRE
Jaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & Europe
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided updates regarding the Company's focus on rare and orphan disease indications: short bowel syndrome (SBS), microvillus inclusion disease (MVID), and cholera. Rare disease indications are the sole focus of Napo Therapeutics, the corporation established by Jaguar in Italy in 2021, with an initial focus on SBS.
- ACCESSWIRE
Jaguar Health Announces Completion of Key Milestone in Process of Establishing Indena S.p.A. as a Reliable Approved Crofelemer Manufacturer
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the required procedure of registering the source of the active pharmaceutical ingredient (API) of crofelemer with the Agenzia Italiana Del Farmaco (AIFA), the Italian Medicines Agency, has been successfully completed. Resultingly, batches of crofelemer API manufactured by Milan, Italy-based Indena S.P.A.
- ACCESSWIRE
Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena Biosciences
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the board of directors has been established for Magdalena Biosciences, Inc., the joint venture recently formed by Jaguar and Filament Health Corp. (NEO:FH, OTCQB:FLHLF) to develop novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults.
